Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Oligandrin is an ent-pimarane type diterpenoid isolated from Croton oligatrus. It is being investigated for its immune-modulatory and antioxidant properties, which contribute to its potential as a natural anticancer agent. Studies have shown that oligandrin can increase peripheral blood mononuclear cell (PBMC) numbers, reduce tumor incidence and burden, and exert a significant antioxidant effect by increasing levels of glutathione (GSH) and superoxide dismutase (SOD). Furthermore, it modulates cytokine levels, decreasing pro-inflammatory cytokines such as Interleukin-6 (IL-6), Interleukin-12 (IL-12), Tumor Necrosis Factor-alpha (TNF-α), and Epidermal Growth Factor (EGF), while increasing the anti-inflammatory cytokine Interferon-gamma (IFN-γ). These actions suggest its utility in treating cancers, particularly breast cancer, by addressing immune system dysfunction and oxidative stress.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on oligandrin.